Literature DB >> 27453374

Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants.

Se In Sung1, Yun Sil Chang1, Ji Young Chun1, Shin Ae Yoon1, Hye Soo Yoo1, So Yoon Ahn1, Won Soon Park2.   

Abstract

OBJECTIVE: To determine whether a nonintervention approach for treating hemodynamically significant patent ductus arteriosus (PDA) is associated with decreased mortality and/or morbidity compared with a mandatory closure approach in extremely low birth weight infants. STUDY
DESIGN: We reviewed the medical records of 178 infants of 23-26 weeks' gestational age with PDA, requiring ventilator treatment, and with hemodynamically significant PDA ≥2 mm in size. Mandatory closure was used during period I (July 2009 to December 2011, n = 81), and nonintervention was used during period II (January 2012 to June 2014, n = 97).
RESULTS: During period I, 64% of infants were first treated with indomethacin, and 82% were ultimately ligated surgically. During period II, no infant was treated with indomethacin and/or ligation. The average postnatal day of PDA closure was day 13 and day 44 during periods I and II, respectively. There was significantly more use of diuretics and fluid restriction during period II compared with period I. There was no difference in mortality or morbidities such as necrotizing enterocolitis or intraventricular hemorrhage. The incidence of bronchopulmonary dysplasia (BPD) and the propensity score adjusted OR of BPD were significantly lower during period II compared with period I.
CONCLUSIONS: Despite longer PDA exposure, nonintervention was associated with significantly less BPD compared with mandatory closure. Additional study is warranted to determine the benefits and risks of non-intervention for the hemodynamically significant PDA in extremely low birth weight infants.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ductal ligation; ibuprofen; indomethacin; patent ductus arteriosus; preterm infant

Mesh:

Substances:

Year:  2016        PMID: 27453374     DOI: 10.1016/j.jpeds.2016.06.046

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Diagnosis and Management of Patent Ductus Arteriosus.

Authors:  Maria Gillam-Krakauer; Jeff Reese
Journal:  Neoreviews       Date:  2018-07

2.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

3.  Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.

Authors:  Melissa Liebowitz; Ronald I Clyman
Journal:  J Pediatr       Date:  2017-04-07       Impact factor: 4.406

Review 4.  Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology.

Authors:  Renjithkumar Kalikkot Thekkeveedu; Milenka Cuevas Guaman; Binoy Shivanna
Journal:  Respir Med       Date:  2017-10-24       Impact factor: 3.415

Review 5.  Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment.

Authors:  Jung S Hwang; Virender K Rehan
Journal:  Lung       Date:  2018-01-27       Impact factor: 2.584

6.  PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.

Authors:  Ronald I Clyman; Melissa Liebowitz; Joseph Kaempf; Omer Erdeve; Ali Bulbul; Stellan Håkansson; Johanna Lindqvist; Aijaz Farooqi; Anup Katheria; Jason Sauberan; Jaideep Singh; Kelly Nelson; Andrea Wickremasinghe; Lawrence Dong; Denise C Hassinger; Susan W Aucott; Madoka Hayashi; Anne Marie Heuchan; William A Carey; Matthew Derrick; Erika Fernandez; Meera Sankar; Tina Leone; Jorge Perez; Arturo Serize
Journal:  J Pediatr       Date:  2018-10-16       Impact factor: 4.406

7.  Prolonged Tracheal Intubation and the Association Between Patent Ductus Arteriosus and Bronchopulmonary Dysplasia: A Secondary Analysis of the PDA-TOLERATE trial.

Authors:  Ronald I Clyman; Joseph Kaempf; Melissa Liebowitz; Omer Erdeve; Ali Bulbul; Stellan Håkansson; Johanna Lindqvist; Aijaz Farooqi; Anup Katheria; Jason Sauberan; Jaideep Singh; Kelly Nelson; Andrea Wickremasinghe; Lawrence Dong; Denise C Hassinger; Susan W Aucott; Madoka Hayashi; Anne Marie Heuchan; William A Carey; Matthew Derrick; Erika Fernandez; Meera Sankar; Tina Leone; Jorge Perez; Arturo Serize
Journal:  J Pediatr       Date:  2020-10-28       Impact factor: 4.406

8.  Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus.

Authors:  Annemarie Kindler; Barbara Seipolt; Antje Heilmann; Ursula Range; Mario Rüdiger; Sigrun Ruth Hofmann
Journal:  Front Pediatr       Date:  2017-12-22       Impact factor: 3.418

9.  Early pulmonary hypertension is a risk factor for bronchopulmonary dysplasia-associated late pulmonary hypertension in extremely preterm infants.

Authors:  Hyun Ho Kim; Se In Sung; Mi Sun Yang; Yea Seul Han; Hye Seon Kim; So Yoon Ahn; Ga Won Jeon; Yun Sil Chang; Won Soon Park
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Outcomes of Left Ventricular Function According to Treatment Response for a Patent Ductus Arteriosus in Preterm Infants.

Authors:  Soo Jung Kang; Young Sun Cho; Seo Jung Hwang; Hyo Jin Kim
Journal:  J Cardiovasc Ultrasound       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.